Home » Stocks » GBS

GBS, Inc. (GBS)

Stock Price: $4.28 USD -0.08 (-1.83%)
Updated Jun 16, 2021 10:31 AM EDT - Market open
Market Cap 53.86M
Revenue (ttm) 441,754
Net Income (ttm) n/a
Shares Out 11.80M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 16
Last Price $4.28
Previous Close $4.36
Change ($) -0.08
Change (%) -1.83%
Day's Open 4.29
Day's Range 4.13 - 4.30
Day's Volume 75,695
52-Week Range 2.44 - 14.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Looking for penny stocks under $5? Check these 3 out The post Hot Penny Stocks to Buy Under $5?

Other stocks mentioned: PROG, RIG
3 days ago - PennyStocks

Global results show 90% of patients are in favor of a saliva-based glucose test Global results show 90% of patients are in favor of a saliva-based glucose test

1 week ago - GlobeNewsWire

- Anticipate Emergency Use Submission for SARS-CoV-2 Antibody Biosensor Test in the Second Half of 2021-

1 month ago - GlobeNewsWire

NEW YORK, April 15, 2021 (GLOBE NEWSWIRE) -- GBS, Inc. (NasdaqGS: GBS), a life sciences company developing non-invasive, real-time point-of-care (POC) diagnostic tests, and the Wyss Institute for Biolog...

2 months ago - GlobeNewsWire

NEW YORK, Feb. 18, 2021 (GLOBE NEWSWIRE) -- GBS Inc. (Nasdaq: GBS), a life sciences company that develops non-invasive, real-time point of care (POC) diagnostic tests for patients and their primary heal...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 28, 2020 (GLOBE NEWSWIRE) -- GBS Inc. (the “Company”) (Nasdaq: GBS), a life sciences company developing non-invasive, real-time diagnostic testing in the hands of patients and their prima...

5 months ago - GlobeNewsWire

GBS and Inhibikase Therapeutics priced late Tuesday.

Other stocks mentioned: IKT
5 months ago - Barrons

Will Trade on the Nasdaq Global Market Under Ticker “GBS” Will Trade on the Nasdaq Global Market Under Ticker “GBS”

5 months ago - GlobeNewsWire

Will Trade on the Nasdaq Global Market Under Ticker “GBS”

5 months ago - GlobeNewswire

GBS, which is developing saliva-based tests for SARS-CoV-2 and diabetes management in China, lowered the proposed deal size for its upcoming IPO on Tuesday. The New York, NY-based company now plans to r...

6 months ago - NASDAQ

About GBS

GBS is a biosensor diagnostic technology company operating worldwide with our COV2 test and across the APAC Region with the biosensor platform comprising of biochemistry, immunology, tumour markers, hormones and nucleic acid diagnostic modalities. We were incorporated under the laws of Delaware on December 5, 2016. Our headquarters are located in New York, New York. GBS is the global licensee and intends to introduce and launch COV2 diagnostic tests across the US, Europe, APAC and the rest of the world through appropriately qualified distributo... [Read more...]

Industry
Medical Devices
IPO Date
Dec 23, 2020
CEO
Harry Simeonidis
Employees
7
Stock Exchange
NASDAQ
Ticker Symbol
GBS
Full Company Profile

Financial Performance

In 2020, GBS, Inc.'s revenue was $188,841, an increase of 100,347.34% compared to the previous year's $188. Losses were -$3.13 million, -57.27% less than in 2019.

Financial Statements